GILD

Why Kite Pharma Soared 64.8% in August

Two businessmen shaking hands and exchanging money

What happened

Shares of Kite Pharma (NASDAQ: KITE) , a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market Intelligence . The huge jump was caused by the news that Kite accepted a buyout offer from biotech giant Gilead Sciences (NASDAQ: GILD) .

So what

Gilead Sciences agreed to acquire Kite for $11.9 billion, or $180 per share. That buyout price represented a 29% premium to its closing price prior to the announcement.

Investors had been expecting it to make a splashy acquisition for a long time. Gilead said that it bought Kite because it would immediately give the company a leadership position in the emerging field of cell therapy.

Gilead's timing looks quite good because Kite is just a few short months away from receiving a go/no-go decision from the Food and Drug Administration related to its lead CAR-T candidate, axicabtagene ciloleucel (axi-cel). Axi-cel is a hopeful treatment for refractory aggressive non-Hodgkin lymphoma. The drug candidate is currently under priority review with the FDA, and it has a PDUFA date of Nov. 29. A marketing authorization application has also been filed in Europe and a decision is expected in 2018.

CEO Dr. John Milligan offered investors the following commentary on why the deal makes sense:

Now what

Gilead's buyout of Kite will be made using cash on hand. Given that the company ended June with more than $36 billion in cash in its bank account, this deal looks to have a very high chance of closing without any issues in the fourth quarter. What's more, it is possible that Gilead could still be on the prowl for other acquisition targets. The company is still struggling to offset the huge sales declines from its hepatitis C franchise. Axi-cel's peak sales estimates are "only" about $1.7 billion. That's a huge number in absolute terms, but it might not be big enough to move Gilead's top line forward.

Congratulations are in order to all long-term Kite shareholders. Anyone smart enough to buy the company's stock after the IPO has earned a more than 500% return in about three years. My suggestion to Kite's shareholders would be to sell today and start the search for the next home-run stock .

10 stocks we like better than Gilead Sciences

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of September 5, 2017

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.